Work

P-046 Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

Year: 2023

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)01664-6

Authors: Paula Rodriguez-Otero, Nisha Joseph, Shaji Kumar, Xavier Leleu, Salomon Manier, Meletios Dimopoulos, Maria-Victoria Mateos, Albert Oriol, Naresh Bumma, Weiying Gong, Pourab Roy, Karen Rodriguez Lorenc, Glenn Kroog, Shawn Sarkaria

Institutions: IGM Biosciences (United States), Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Médica Aplicada, Colorado Blood Cancer Institute, Winship Cancer Institute, Mayo Clinic, Sarah Cannon Research Institute, Université de Lille, Centre Hospitalier Universitaire de Lille, National and Kapodistrian University of Athens, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Institut Català d'Oncologia, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Regeneron (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4387003961

Cites:

Cited by:

Related to: 10